Results 71 to 80 of about 18,455 (220)

Peptide receptor radionuclide therapy for metastatic paragangliomas

Medical Oncology, 2016
There is little evidence to direct the management of malignant paragangliomas (mPGL) beyond initial surgical treatment. Peptide receptor radionuclide therapy (PRRT), using somatostatin analogues, is effective in other neuroendocrine tumours, but data on its efficacy in treating mPGL are scarce.
Pinato D. J., Black J. R. M., Ramaswami R., Tan T. M., Adjogatse D., Sharma R.   +5 more
openaire   +4 more sources

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Kidney Protection with the Radical Scavenger α₁-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy

Antioxidants, 2021
α1-Microglobulin (A1M) is an antioxidant found in all vertebrates, including humans. It has enzymatic reductase activity and can scavenge radicals and bind free heme groups.
Amanda Kristiansson, Anders Örbom, Oskar Vilhelmsson Timmermand, Jonas Ahlstedt, Sven-Erik Strand, Bo Åkerström   +5 more
doaj   +1 more source

CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer [PDF]

, 2019
Background: Molecular targeting remains to be a promising approach in oncology. Overexpression of G protein-coupled receptors (GPCRs) in human cancer is offering a powerful opportunity for tumor-selective imaging and treatment employing nuclear medicine.
Bandholtz, Sebastian, Beindorff, Nicola, Brenner, Winfried, Erdmann, Sarah, Exner, Samantha, Grötzinger, Carsten, Gómez, Juan Daniel Castillo, Hacht, Jan Lennart von, Koziolek, Eva Jolanthe, Niederstadt, Lars, Prasad, Sonal, Reinicke, Sandy, Wagener, Asja   +12 more
core   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Seleksi Model pada Peptide-receptor Radionuclide Therapy dengan 177Lu-DOTATATE untuk Dosimetri Ginjal

Jurnal Fisika Flux, 2022
Seleksi model merupakan aspek penting dari analisis data farmakokinetik. Seleksi model dilakukan untuk memperoleh fungsi terbaik yang selanjutnya digunakan dalam perhitungan nilai TIACs pada dosimetri individu.
Rahmatul Hanifah, Nur Atikah, M Zaidi Anwari, M Dlorifun Naqiyyun, Ade Riana, Deni Hardiansyah   +5 more
doaj   +1 more source

Polish Experience in Peptide Receptor Radionuclide Therapy

, 2012
During the period from April 2004 to December 2010, 358 patients underwent peptide receptor radionuclide therapy (PRRT) ((90)Y-DOTATATE, (177)Lu-DOTATATE, and (90)Y/(177)Lu-DOTATATE) in Poland.The majority of patients underwent (90)Y-DOTATATE therapy (n = 177) with progression-free survival (PFS)/time to progression (TTP) of 17-44 months and overall ...
Kunikowska, Jolanta, Królicki, Leszek, Sowa-Staszczak, Anna, Hubalewska-Dydejczyk, Alicja, Pawlak, Dariusz, Mikołajczak, Renata, Handkiewicz-Junak, Daria, Szaluś, Norbert, Kamiński, Grzegorz, Cwikla, Jaroslaw, Jakuciński, Maciej, Lukiewicz, Anna, Kowalska, Aldona, Gut, Pawel   +13 more
openaire   +3 more sources

Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents

Chemistry – A European Journal, EarlyView.
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley   +1 more source

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate [PDF]

, 2009
Adequate dosimetry is mandatory for effective and safe peptide receptor radionuclide therapy (PRRT). Besides the kidneys, the bone marrow is a potentially dose-limiting organ.
Flavio Forrer, Eric P. Krenning, Peter P. Kooij, Bert F. Bernard, Mark Konijnenberg, Willem H. Bakker, Jaap J. M. Teunissen, Marion de Jong, Kirsten van Lom, Wouter W. de Herder, Dik J. Kwekkeboom   +10 more
core   +1 more source

Carbon Dots for Cancer Theranostics: Synthesis Strategies, Luminescence Properties, and Advances in Bioimaging‐Guided Diagnosis and Therapy

Chemistry – A European Journal, EarlyView.
Lighting up the path to precision oncology: This review comprehensively summarizes the rational design of carbon dots (CDs), elucidating how core size, surface chemistry, and heteroatom doping dictate their luminescence mechanisms. Special emphasis is placed on engineering NIR‐II emissive CDs for deep‐tissue imaging.
Zekun Yan, Yupeng Liu, Jinyun Tan, Songnan Qu   +3 more
wiley   +1 more source